Evidence map›Paper›PMID 42611622›Full record

ArticleActa crystallographica. Section C, Structural chemistry2026

YK-4-250, a synthetic telmisartan-tempol conjugate: crystal structure of a stabilized free radical containing an angiotensin AT

Simon Friedrich, Yali Kong, Faik N Musayev, Milton L Brown, B Frank Gupton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta crystallographica. Section C, Structural chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simon FriedrichDepartment of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23220, USA.
Yali KongDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, USA.
Faik N MusayevDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
Milton L BrownDepartment of Medicine, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23501, USA.
B Frank GuptonMedicines for All Institute, Virginia Commonwealth University, Richmond, VA 23284, USA.

Funding

Development of YK-4-250, a radiation mitigator of GI-ARSU01AI187033 · NIAID · OLD DOMINION UNIVERSITY · PI Milton L. Brown, Vidya P. Kumar · 2025 to 2026
$1.1M
National Institutes of Health, National Institute of Allergy and Infectious Diseases 1U01AI187033-01NIAID NIH HHS U01 AI187033
6 · The paper itself

Abstract

We report the first crystal structure of the telmisartan-tempol conjugate 2,2,6,6-tetramethyl-1-(λ'-oxidaneyl)piperidin-4-yl 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl]-[1,1'-biphenyl]-2-carboxylate free radical (YK-4-250, C

Indexed as

Angiotensin II Type 1 Receptor BlockersBenzimidazolesBenzoatesCyclic N-OxidesReceptor, Angiotensin, Type 1Crystallography, X-RayFree RadicalsHydrogen BondingMolecular StructureSpin LabelsTelmisartanAngiotensin II Type 1 Receptor BlockersBenzimidazolesBenzoatesCyclic N-OxidesFree RadicalsReceptor, Angiotensin, Type 1Spin LabelsTelmisartantempolangiotensin receptor blockerARBcrystal structureradiation mitigatorradical stabilizationsolid-state characterization

Identifiers

PMID42611622
PMCPMC13543282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.